Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Kazia Therapeutics

Tracked across 2 events · 29 articles · First seen Jul 20, 2026 · Last active Sep 01, 2026

Sentiment
55
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 40
Business
Impact: Kazia is the issuer and primary beneficiary of the offering, raising $40 million upfront with potential for $80 million more from warrant exercises. The capital will fund clinical development of paxalisib, enhancing its financial position and supporting its pipeline.
Jul 20, 2026 · 22 articles
4 70
Tech
Impact: Kazia is the developer of paxalisib and the primary beneficiary of the positive preclinical data, which supports its advancement into a Phase 2 trial and strengthens its pipeline.
Jul 20, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Kazia Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.